Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Notes underwriting agrmnt
EMMAUS LIFE SCIENCES, INC. Create: Alert

All | News | Filings
Date FiledTypeDescription
07/08/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "PRESS RELEASE OF EMMAUS LIFE SCIENCES, INC."
07/03/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "PRESS RELEASE OF EMMAUS LIFE SCIENCES, INC."
06/24/2019 8-K Quarterly results
03/11/2019 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Form of Amended and Restated 10% Senior Secured Debenture",
"Form of Amended and Restated Common Stock Purchase Warrant",
"Securities Amendment Agreement among Emmaus Life Sciences, Inc. and the Holders thereunder",
"Media Contacts:"
01/07/2019 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger and Reorganization, by and among MYnd Analytics, Inc., Athena Merger Subsidiary, Inc. and Emmaus Life Sciences, Inc",
"Form of Emmaus Voting Agreement, including form of irrevocable proxy",
"Form of MYnd Voting Agreement, including form of irrevocable proxy",
"Form of Emmaus Lock-Up Agreement",
"Form of MYnd Lock-Up Agreement",
"CFO, Emmaus Life Sciences, Inc."
12/20/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amendment No. 2 to By-Laws of Emmaus Life Sciences, Inc. (Formerly AFH Acquisition IV, Inc.)"
10/15/2018 8-K Quarterly results
09/28/2018 8-K Quarterly results
09/17/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Form of 10% Senior Secured Debenture",
"Form of Common Stock Purchase Warrant",
"Securities Purchase Agreement among Emmaus Life Sciences, Inc. and the Purchasers thereunder",
"Form of Security Agreement among Emmaus Life Sciences, Inc., Emmaus Medical, Inc., Newfield Nutrition Corporation and the holders of 10% Senior Secured Debentures",
"Form of Subsidiary Guarantee among Emmaus Medical, Inc., Newfield Nutrition Corporation and the holders of 10% Senior Secured Debentures",
"Fee Agreement made as of August 24, 2018 between Emmaus Life Sciences, Inc. and T.R. Winston & Company, LLC"
07/19/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/18/2018 8-K Appointed a new director
04/04/2018 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Securities Repurchase Agreement between Emmaus Life Sciences, Inc. and Sarissa Capital Offshore Master Fund LP"
03/07/2018 8-K Entry into a Material Definitive Agreement
03/06/2018 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Payoff Letter"
01/05/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Securities Purchase Agreement",
"12.5% Senior Secured Convertible Note",
"Common Stock Purchase Warrant",
"Security Agreement",
"Intellectual Property Security Agreement",
"Guaranty",
"Registration Rights Agreement"
09/06/2017 8-K Quarterly results
07/10/2017 8-K Form 8-K - Current report:
06/16/2017 8-K Form 8-K - Current report
06/05/2017 8-K Form 8-K - Current report
05/19/2017 8-K Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Termination Notice"
04/18/2017 8-K Form 8-K - Current report
01/20/2017 8-K Form 8-K - Current report
01/04/2017 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Phase 3 Study Data"
12/19/2016 8-K Form 8-K - Current report
12/15/2016 8-K Form 8-K - Current report
12/02/2016 8-K Form 8-K - Current report
10/24/2016 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11, Other Events
10/07/2016 8-K Form 8-K - Current report
09/16/2016 8-K Entry into a Material Definitive Agreement
09/13/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Emmaus Life Sciences Submits New Drug Application for Sickle Cell Disease Treatment"
03/18/2016 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Termination Agreement, among the registrant, Yutaka Niihara and T.R. Winston & Company, LLC"
03/06/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to the Company’s Bylaws"
07/17/2012 8-K Regulation FD Disclosure
Docs: "European Commission Grants Orphan Medicinal Product Designation for Emmaus Medical’ s Sickle Cell Treatment -Company Provides Update on Phase III U.S. FDA Clinical Trials for the Treatment of Sickle Cell Disease- TORRANCE, Calif., July 17, 2012 — Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, and subsidiary of Emmaus Life Sciences, Inc., today announced that the European Commission has granted Orphan Medicinal Product designation for the company’ s investigational drug Levoglutamide for the treatment of sickle cell disease. The EC designation follows the recommendation of the European Medicines Agency’ s Committee for Orphan Medicinal Products announced in May. Sickle cell disease affects approximately 2.5 in 10,000 people in the European Uni..."
06/06/2012 8-K Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation o...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy